Mihael Polymeropoulos, Vanda Pharmaceuticals CEO
February 5, 2024 03:44 PM EST
Pharma
FDA+

Van­da takes is­sue with FDA's re­lay of de­fi­cien­cies for new Het­lioz in­di­ca­tion

Lia DeGroot

Van­da Phar­ma­ceu­ti­cals said on Mon­day that the FDA no­ti­fied the com­pa­ny of sev­er­al de­fi­cien­cies in the sup­ple­men­tal new drug ap­pli­ca­tion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times